Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographics and clinical characteristics for patients treated with and without PORT before and after PSM

From: Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database

Demographic or clinical characteristic Before PSM After PSM
No PORT
(N = 2090)
PORT (N=1244) P No PORT
(N = 744)
PORT
(N = 744)
P
Age, years (range) 65.5 (22–89) 65.7 (28–93) 0.581 66.4 (62–89) 65.7 (28–90) 0.692
Gender
 Male 1026 (62.0%) 629 (38.0%) 0.411 355 (48.2%) 381 (51.8%) 0.178
 Female 1064 (63.4%) 615 (36.6%) 389 (51.7%) 363 (48.3%)
Race
 White 1689 (62.8%) 999 (37.2%) 0.720 604 (49.9%) 607 (50.1%) 0.842
 Nonwhite 401 (62.1%) 245 (37.9%) 140 (50.5%) 137 (49.5%)
Marital status
 Married 1185 (59.4%) 810 (50.6%) 0.000 465 (50.6%) 454 (49.4%) 0.557
 others 905 (67.6%) 434 (32.4%) 279 (49.0%) 290 (51.0%)
Insurance
 Insured 1261 (61.7%) 783 (38.3%) 0.135 462 (49.5%) 471 (50.5%) 0.629
 others 829 (64.3%) 461 (35.7%) 282 (50.8%) 273 (49.2%)
Laterality
 Left 976 (63.9%) 552 (36.1%) 0.192 317 (47.7%) 347 (52.3%) 0.118
 Right 1114 (61.7%) 692 (38.3%) 427 (51.8%) 397 (48.2%)
Location
 Upper lobe 1229 (61.5%) 768 (38.5%) 0.084 436 (48.9%) 455 (51.1%) 0.587
 Middle lobe 89 (58.9%) 62 (41.1%) 36 (52.9%) 32 (47.1%)
 Lower lobe 772 (65.1%) 414 (34.9%) 272 (51.4%) 257 (48.6%)
Tumor size, cm (range) 3.8 (0.1–19.0) 3.7 (0.5–15) 0.340 3.7 (0.1–15) 3.8 (0.5–15) 0.670
LN positive (range) 3.4 (1–41) 3.8 (1–30) 0.000 3.4 (1–33) 3.5 (1–24) 0.062
LN examined (range) 12.2 (1–90) 11.6 (1–64) 0.006 11.9 (1–68) 12.0 (1–61) 0.473
% of LN positive (range) 35.4 (1.4–100) 41.2 (1.7–100) 0.000 35.5 (1.4–100) 35.8 (1.7–100) 0.380
Histology
 Adenocarcinoma 1423 (61.5%) 891 (38.5%) 0.097 478 (48.1%) 515 (51.9%) 0.110
 Squamous cell carcinoma 505 (65.2%) 270 (34.8%) 204 (54.4%) 171 (45.6%)
 Adenosquamous and large cell carcinoma 162 (66.1%) 83 (33.9%) 62 (51.7%) 58 (48.3%)
Differentiation
 Well differentiated 131 (72.4%) 50 (27.6%) 0.012 20 (40.8%) 29 (59.2%) 0.548
 Moderately differentiated 930 (61.5%) 581 (38.5%) 354 (51.1%) 339 (48.9%)
 Poorly differentiated 969 (62.2%) 589 (37.8%) 354 (49.7%) 358 (50.3%)
 Undifferentiated 60 (71.4%) 24 (28.6%) 16 (47.1%) 18 (52.9%)
Surgical procedure
 Sublobectomy 145 (51.4%) 137 (48.6%) 0.000 50 (51.0%) 48 (49.0%) 0.972
 Lobectomy 1741 (62.9%) 1026 (37.1%) 643 (49.9%) 646 (50.1%)
 Pneumonectomy 204 (71.6%) 81 (28.4%) 51 (50.5%) 50 (49.5%)
T stage (sixth edition)
 T1 629 (61.3%) 397 (38.7%) 0.359 235 (50.6%) 229 (49.4%) 0.908
 T2 1341 (63.6%) 768 (36.4%) 468 (49.8%) 471 (50.2%)
 T3 120 (60.3%) 79 (39.7%) 41 (48.2%) 44 (51.8%)
  1. LN lymph node, PSM propensity score-matching, PORT postoperative radiotherapy